Guanabenz and methyldopa on hypertension and cardiac performance

Barry R. Walker, Rajnikant S. Shah, K Ramanathan, Svetislav K. Vanov, Richard H. Helfant

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

In previous placebo-controlled studies, guanabenz was shown to be a safe and effective antihypertensive drug without acute effects on cardiac function. In view of its therapeutic advantages, a double-blind comparison of guanabenz with methyldopa was performed in a group of 36 patients over 6 mo. Both drugs produced statistically and clinically significant decreases in blood pressure with similar side effects. No laboratory or electrocardiographic abnormalities were found other than positive Coombs' tests which developed in 3 patients during methyldopa therapy. Cardiac performance in 26 of the patients, as measured by noninvasive techniques, showed no significant changes from either drug except for a progressive and statistically significant increase in systolic time interval (QS2) and the ratio of the pre-ejection period to left ventricular ejection time (PEPILVET) during methyldopa therapy. For an additional 6 mo, continued efficacy and safety were shown under open conditions in those patients who had received guanabenz. The study suggests that guanabenz may be an important new antihypertensive drug because of effectiveness, absence of adverse cardiac effects, and paucity of side effects.

Original languageEnglish (US)
Pages (from-to)868-874
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume22
Issue number6
DOIs
StatePublished - Jan 1 1977
Externally publishedYes

Fingerprint

Guanabenz
Methyldopa
Hypertension
Antihypertensive Agents
Coombs Test
Systole
Pharmaceutical Preparations
Therapeutics
Placebos
Blood Pressure
Safety

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Guanabenz and methyldopa on hypertension and cardiac performance. / Walker, Barry R.; Shah, Rajnikant S.; Ramanathan, K; Vanov, Svetislav K.; Helfant, Richard H.

In: Clinical Pharmacology and Therapeutics, Vol. 22, No. 6, 01.01.1977, p. 868-874.

Research output: Contribution to journalArticle

Walker, Barry R. ; Shah, Rajnikant S. ; Ramanathan, K ; Vanov, Svetislav K. ; Helfant, Richard H. / Guanabenz and methyldopa on hypertension and cardiac performance. In: Clinical Pharmacology and Therapeutics. 1977 ; Vol. 22, No. 6. pp. 868-874.
@article{3ca480981ee74847bcd9159f03612a4d,
title = "Guanabenz and methyldopa on hypertension and cardiac performance",
abstract = "In previous placebo-controlled studies, guanabenz was shown to be a safe and effective antihypertensive drug without acute effects on cardiac function. In view of its therapeutic advantages, a double-blind comparison of guanabenz with methyldopa was performed in a group of 36 patients over 6 mo. Both drugs produced statistically and clinically significant decreases in blood pressure with similar side effects. No laboratory or electrocardiographic abnormalities were found other than positive Coombs' tests which developed in 3 patients during methyldopa therapy. Cardiac performance in 26 of the patients, as measured by noninvasive techniques, showed no significant changes from either drug except for a progressive and statistically significant increase in systolic time interval (QS2) and the ratio of the pre-ejection period to left ventricular ejection time (PEPILVET) during methyldopa therapy. For an additional 6 mo, continued efficacy and safety were shown under open conditions in those patients who had received guanabenz. The study suggests that guanabenz may be an important new antihypertensive drug because of effectiveness, absence of adverse cardiac effects, and paucity of side effects.",
author = "Walker, {Barry R.} and Shah, {Rajnikant S.} and K Ramanathan and Vanov, {Svetislav K.} and Helfant, {Richard H.}",
year = "1977",
month = "1",
day = "1",
doi = "10.1002/cpt1977226868",
language = "English (US)",
volume = "22",
pages = "868--874",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Guanabenz and methyldopa on hypertension and cardiac performance

AU - Walker, Barry R.

AU - Shah, Rajnikant S.

AU - Ramanathan, K

AU - Vanov, Svetislav K.

AU - Helfant, Richard H.

PY - 1977/1/1

Y1 - 1977/1/1

N2 - In previous placebo-controlled studies, guanabenz was shown to be a safe and effective antihypertensive drug without acute effects on cardiac function. In view of its therapeutic advantages, a double-blind comparison of guanabenz with methyldopa was performed in a group of 36 patients over 6 mo. Both drugs produced statistically and clinically significant decreases in blood pressure with similar side effects. No laboratory or electrocardiographic abnormalities were found other than positive Coombs' tests which developed in 3 patients during methyldopa therapy. Cardiac performance in 26 of the patients, as measured by noninvasive techniques, showed no significant changes from either drug except for a progressive and statistically significant increase in systolic time interval (QS2) and the ratio of the pre-ejection period to left ventricular ejection time (PEPILVET) during methyldopa therapy. For an additional 6 mo, continued efficacy and safety were shown under open conditions in those patients who had received guanabenz. The study suggests that guanabenz may be an important new antihypertensive drug because of effectiveness, absence of adverse cardiac effects, and paucity of side effects.

AB - In previous placebo-controlled studies, guanabenz was shown to be a safe and effective antihypertensive drug without acute effects on cardiac function. In view of its therapeutic advantages, a double-blind comparison of guanabenz with methyldopa was performed in a group of 36 patients over 6 mo. Both drugs produced statistically and clinically significant decreases in blood pressure with similar side effects. No laboratory or electrocardiographic abnormalities were found other than positive Coombs' tests which developed in 3 patients during methyldopa therapy. Cardiac performance in 26 of the patients, as measured by noninvasive techniques, showed no significant changes from either drug except for a progressive and statistically significant increase in systolic time interval (QS2) and the ratio of the pre-ejection period to left ventricular ejection time (PEPILVET) during methyldopa therapy. For an additional 6 mo, continued efficacy and safety were shown under open conditions in those patients who had received guanabenz. The study suggests that guanabenz may be an important new antihypertensive drug because of effectiveness, absence of adverse cardiac effects, and paucity of side effects.

UR - http://www.scopus.com/inward/record.url?scp=0017590225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017590225&partnerID=8YFLogxK

U2 - 10.1002/cpt1977226868

DO - 10.1002/cpt1977226868

M3 - Article

VL - 22

SP - 868

EP - 874

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -